Ocuphire Pharma Investor Day Presentation Deck
Nyxol® with Low-Dose Pilocarpine (LDP) as Adjunct Therapy
Moderate Action on Iris Dilator and Iris Sphincter Muscles for Near Vision Improvement
0.75% Nyxol
P
79
+
Flo
C
0.4%
0.4% LDP
Iris Dilator
Muscle
Inhibition
Iris Sphincter
Muscle
Activation
Source: 1) Nyxol® data from 9 completed trials; Pilocarpine Product label and Literature
Evening drop
Daytime drop
●
●
●
●.
●
●
●
●
●
Phentolamine (alpha1/2 antagonist)
Novel MOA on iris dilator with 24+ hour durability
Moderate 1+mm pupil reduction
No daytime redness
Well-tolerated with no systemic effects
Stable, preservative-free, single-use vial
Pin-hole target is 2 to 3 mm with
contributions from each MOA
Pilocarpine (cholinergic agonist)
Known MOA on sphincter (and ciliary) muscle as
potent miotic at approved doses (1%, 2%, 4%)
Low concentration avoids known safety issues:
➤ headache and browache
➤ redness
➤ accommodative spasm causing loss of
distance vision especially at night
Ocuphire
PHARMAView entire presentation